EM
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences | 2025 | 177 | 85 | |||
| Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence | Nature biomedical engineering | 2025 | 20 | 12 | |||
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | 2024 | 296 | 268 | |||
| Brain Metastases from Genito-Urinary Cancers in the Canton of Geneva (Switzerland) : Study of Incidence, Management and Outcomes | Cancers | 2024 | 87 | 140 | |||
| Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial | Nature cancer | 2024 | 379 | 3 | |||
| PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma | 2023 | 236 | 514 | ||||
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | 2023 | 324 | 140 | |||
| Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread | Neurology Genetics | 2021 | 333 | 94 | |||
| Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) | JCI insight | 2021 | 263 | 178 | |||
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | 2021 | 343 | 207 | |||
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | 2020 | 483 | 307 | |||
| Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma | OncoImmunology | 2020 | 458 | 299 | |||
| Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients | Frontiers in Oncology | 2020 | 352 | 152 | |||
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | 2019 | 848 | 601 | |||
| Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients | Cancers | 2019 | 370 | 206 | |||
| Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models | OncoImmunology | 2018 | 433 | 1 | |||
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | 2018 | 665 | 363 | |||
| Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing | PloS one | 2016 | 669 | 676 | |||
| Ipilimumab-related hypophysitis may precede severe CNS immune attack | Annals of Oncology | 2016 | 459 | 0 |
